Clin2
NCT06225232Possibly a fitRecruiting

Psilocybin for cannabis use disorder

Cannabis Use Disorder, ModerateCannabis Use Disorder, Severe

Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.

This trial tests whether a single dose of psilocybin (a psychedelic compound) can help people with moderate to severe cannabis use disorder reduce or stop their cannabis use. You will receive the drug in a supervised setting and have follow-up check-ins.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
16 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You are 18 to 65 years old.
  • You have been diagnosed with moderate or severe cannabis use disorder and want to cut down or quit.
  • You are generally healthy (no serious heart, liver, or kidney problems) and not pregnant or nursing.
  • You have not used psychedelics like psilocybin or LSD in the past year, and have used them less than 5 times in your life.
  • You are not currently taking certain medications like stimulants, antipsychotics, or benzodiazepines (SSRIs are okay if stable).
  • You can speak and read English, have a stable home, and can have someone stay with you overnight after the dosing sessions.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06907979Recruiting
Cannabis use and emotion processing study

This study looks at how heavy cannabis use affects the way you process emotions. You may be able to join if you use cannabis most days, meet criteria for cannabis use disorder, and are not currently in treatment for it. Participants will have brain scans and mild brain stimulation.

Auburn, Alabama
NCT05859347Recruiting
Brain stimulation study for cannabis use disorder

This trial tests whether a treatment called repetitive transcranial magnetic stimulation (a non-surgical magnetic stimulation to the brain) can help people reduce or stop cannabis use. You may be eligible if you have cannabis use disorder and meet specific safety and symptom criteria.

Toronto, Ontario
NCT07405606Not yet recruiting· Phase 2
Psilocybin therapy for depression and alcohol use disorder

This study tests whether a drug called psilocybin, given along with therapy, can help people who have both major depression and alcohol use disorder. You may be a good fit if you have tried other treatments or don't want to start new medications.

Toronto, Ontario
NCT06660381Recruiting· Phase 1
Psilocybin therapy for cannabis use disorder

This study tests if psilocybin (a substance that can change how you think and feel) can help people reduce or stop using cannabis. You will receive support and be monitored closely throughout the trial.

Baltimore, Maryland
NCT06160232Recruiting· Phase 2
Psilocybin therapy for severe alcohol use disorder

This trial tests whether psilocybin, a psychedelic substance, combined with talk therapy can help people with severe alcohol use disorder stop or reduce drinking. Participants will first complete a 4-week inpatient detox program before receiving psilocybin in a supervised setting.

Brussels
NCT06349083Recruiting· Phase 2
Psilocybin-assisted treatment for alcohol use disorder

This study tests whether psilocybin, a psychedelic drug, combined with therapy can help people reduce or stop drinking. It aims to understand how psilocybin affects the brain and behavior in people with alcohol use disorder.

New York, New York

Hear when a new Cannabis Use Disorder, Moderate trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.